Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis

Immunity & Ageing

Table 1 Age adjusted TL in SSc patients and controls

	N	TL (z-score)¹	p	<Percentile 10th n (%)	p
Healthy Controls	68	−0.00 [− 0.28, 0.31]	Ref	6 (9%)	Ref
SSc patients	174	−0.84 [−1.15, − 0.62]	< 0.0001	71 (41%)	< 0.0001
dcSSc	69	−0.84 [−1.93, 0.05]	< 0.0001	29 (42%)	< 0.0001
lcSSc	105	−0.85 [−1,57, 0,18]	< 0.0001	40 (38%)	0.0001
ILD	57	−1.03 [− 1.63, −0.42]	< 0.0001	24 (41%)	< 0.0001
No ILD	117	−0.83 [−1.62, 0.32]	0.004	45 (39%)	0.0001
ATA+	54	−1.04 [− 1.6, −0.03]	0.0002	22 (41%)	< 0.0001
ACA+	62	−0,63 [−1.30, 0.47]	0.025	20 (32%)	0.0008
Comorbidity²	115	−0.85 [−1.58, 0.18]	0.0001	44 (38%)	< 0.0001
No comorbidity	59	−0.84 [−2.06, − 0.02]	0.0003	27 (28%)	< 0.0001

¹Median (IQR, 25–75%). ² Comorbidity includes hypertension, hypercholesterolemia, diabetes, smoking or major adverse cardiovascular events (MACE). lcSSc: limited cutaneous SSc. dcSSc: diffuse cutaneous SSc. ILD: Interstitial lung disease. NS: Non significant. ATA+ (anti-topoisomerase-I positive), ACA+ (anti-centromeric protein B positive)

ISSN: 1742-4933